# NEOsphere Biotechnologies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/neosphere-biotechnologies

- Industry: Biotechnology
- Headquarters: Germany
- Website: www.neospherebiotechnologies.com
- Total disclosed funding: $6.1M
- Latest round: Series A (Sep 21, 2022)
- Investors on record: 4

## About

Based in Planegg, Germany, and founded in 2022 by Prof Dr. Henrik Daub (CSO) and Dr. Jutta Fritz (CBO), NEOsphere Biotechnologies GmbH develops small molecule degraders as therapeutic agents. In August 2022, the firm raised EUR 6 million in Series A funding led by investor Ventura BioMed Investors.

The company offers an integrated proteomics platform that helps in developing therapeutic medicine which can eliminate TPD (Targeted protein degradation). Additionally, the firm conducts a deep proteomic screening by exploring degrader targets and degrader chemistries to unlock the therapeutic potential of degrader molecules which in return helps in drug development.

The company plans to use the August 2022 funding to support its platform clinical identification.

## Funding rounds

- Series A, Sep 21, 2022 — Ventura BioMed Investors, ELBE Beteiligungsgesellschaft mbH, F.E.L. Invest GmbH, BEAM Private Equity AG
- Series A, Jul 25, 2022, $6.1M — Ventura BioMed Investors

## Investors

- Ventura BioMed Investors (https://capitalatlas.ai/funds/ventura-biomed-investors) — Series A
- ELBE Beteiligungsgesellschaft mbH — Series A
- F.E.L. Invest GmbH — Series A
- BEAM Private Equity AG — Series A